StockWatch: FDA Panel Enables Accelerated OK for Biogen ALS Drug
Mixed votes from an FDA advisory panel may help Biogen secure accelerated approval of ALS drug tofersen, licensed from Ionis Pharmaceuticals.
Stay updated with breaking news from Eunk Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mixed votes from an FDA advisory panel may help Biogen secure accelerated approval of ALS drug tofersen, licensed from Ionis Pharmaceuticals.
Operator Good day and welcome to the alboreto pharma first quarter 2021 earnings conference call. [Operator Instructions] At this time, I would like to turn the conference over to Mr. Paul. Please go ahead, sir. Paul S. Bavier -- Interim President, General Counsel And Secretary Thank you, operator and good morning everyone. Thank you for joining today's call. This morning, Alberto issued a press release highlighting its recent business accomplishments and reporting its financial results for the first quarter ended March 31 2021. This press release is accessible via the company's website at w...
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.[Alexion Pharmaceuticals] December 14, 2020 AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisit...